The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Hepatitis B virus suppresses toll-like receptor–mediated innate immune responses in murine parenchymal and nonparenchymal liver cells #
Open accessAbstract
We have previously shown that Toll-like receptor (TLR)-activated murine nonparenchymal liver cells [(NPC); Kupffer cells (KC), liver sinusoidal endothelial cells (LSEC)] can suppress hepatitis B virus (HBV) replication. Therefore, the aim of this study was to investigate whether HBV has the ability to counteract the TLR-mediated control of its replication. Freshly purified murine hepatocytes and NPCs obtained from C57BL6 mice were stimulated by TLR 1-9 ligands in the presence or absence of hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), HBV virions, or supernatants from HBV-producing HBV-Met cells, and HBV replication was suppressed by anti- hepatitis B virus X protein (HBx) small interfering RNA (siRNA) in HBV-Met cells. Supernatants were collected and tested for antiviral cytokines by viral protection assay. HBV gene expression and replication was analyzed by southern blot. RNA and proteins were analyzed by quantitative reverse transcription polymerase chain reaction (RT-PCR) or western blot and enzyme-linked immunosorbent assay, respectively. Pretreatment of hepatocytes and NPCs with HBV-Met cells supernatants, HBsAg, HBeAg, or HBV virions almost completely abrogated TLR-induced antiviral activity, which correlated with suppression of interferon beta (IFN-β) production and subsequent interferon-stimulated gene induction as well as suppressed activation of interferon regulatory factor 3 (IRF-3), nuclear factor kappa B (NF-κB), and extracellular signal-regulated kinase (ERK) 1/2. In HBV-infected HBV-Met cells, TLR stimulation did not induce antiviral cytokines in contrast to primary hepatocytes. TLR-stimulated expression of proinflammatory cytokines [tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6)], and activation of IRF-3 was suppressed after up-regulation of HBV replication in HBV-Met cells. Accordingly, suppression of HBV replication by siRNA led to activation or expression of proinflammatory transcription factors and cytokines. Conclusion: Our data indicate that HBV can suppress the TLR-induced antiviral activity of liver cells. This has major implications for the interaction between HBV and the immune system. (Hepatology 2009.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genomic analysis of the host response to hepatitis C virus infection
Su, A. I., Pezacki, J. P., Wodicka, L., Brideau, A. D., Supekova, L., Thimme, R., Wieland, S., Bukh, J., Purcell, R. H., Schultz, P. G., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202608199 · Cited by 1,161
Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease
Foy, E., Li, K., Wang, C., Sumpter, R., Ikeda, M., Lemon, S. M., & Gale, M. (2003) · Science · doi:10.1126/science.1082604 · Cited by 788
Genomic analysis of the host response to hepatitis B virus infection
Wieland, S., Thimme, R., Purcell, R. H., & Chisari, F. V. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401771101 · Cited by 652
How Toll-like receptors signal: what we know and what we don’t know
O’Neill, L. A. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.11.012 · Cited by 613
Akira, S. (2003) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00013-4 · Cited by 584
A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling
Bowie, A., Kiss-Toth, E., Symons, J. A., Smith, G. L., Dower, S. K., & O'Neill, L. A. J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.160027697 · Cited by 466
Toll-Like Receptor Signaling Inhibits Hepatitis B Virus Replication In Vivo
Isogawa, M., Robek, M. D., Furuichi, Y., & Chisari, F. V. (2005) · Journal of Virology · doi:10.1128/jvi.79.11.7269-7272.2005 · Cited by 442
DNA Microarray Analysis of Chimpanzee Liver during Acute Resolving Hepatitis C Virus Infection
Bigger, C. B., Brasky, K. M., & Lanford, R. E. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.7059-7066.2001 · Cited by 442
Guidotti, L. G., Ando, K., Hobbs, M. V., Ishikawa, T., Runkel, L., Schreiber, R. D., & Chisari, F. V. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3764 · Cited by 412
The Poxvirus Protein A52R Targets Toll-like Receptor Signaling Complexes to Suppress Host Defense
Harte, M. T., Haga, I. R., Maloney, G., Gray, P., Reading, P. C., Bartlett, N. W., Smith, G. L., Bowie, A., & O'Neill, L. A. J. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021652 · Cited by 370
Cited by
Yuen, M.-F., Chen, D.-S., Dusheiko, G. M., Janssen, H. L. A., Lau, D. T. Y., Locarnini, S. A., Peters, M. G., & Lai, C.-L. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.35 · Cited by 814
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma
Arzumanyan, A., Reis, H. M. G. P. V., & Feitelson, M. A. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3449 · Cited by 800
Living in the liver: hepatic infections
Protzer, U., Maini, M. K., & Knolle, P. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3169 · Cited by 560
Therapeutic strategies for hepatitis B virus infection: towards a cure
Fanning, G. C., Zoulim, F., Hou, J., & Bertoletti, A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0037-0 · Cited by 557
Bertoletti, A., & Ferrari, C. (2012) · Gut · doi:10.1136/gutjnl-2011-301073 · Cited by 477
Yu, X., Lan, P., Hou, X., Han, Q., Lu, N., Li, T., Jiao, C., Zhang, J., Zhang, C., & Tian, Z. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.018 · Cited by 356
Not interferon, but interleukin‐6 controls early gene expression in hepatitis B virus infection†‡
Hösel, M., Quasdorff, M., Wiegmann, K., Webb, D., Zedler, U., Broxtermann, M., Tedjokusumo, R., Esser, K., Arzberger, S., Kirschning, C. J., et al. (2009) · Hepatology · doi:10.1002/hep.23226 · Cited by 347
Gish, R. G., Given, B. D., Lai, C.-L., Locarnini, S. A., Lau, J. Y. N., Lewis, D. L., & Schluep, T. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.06.008 · Cited by 259
3D microfluidic liver cultures as a physiological preclinical tool for hepatitis B virus infection
Ortega-Prieto, A. M., Skelton, J. K., Wai, S. N., Large, E., Lussignol, M., Vizcay-Barrena, G., Hughes, D., Fleck, R. A., Thursz, M., Catanese, M. T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02969-8 · Cited by 236
Differential Expression of Toll-Like Receptors in Patients With Irritable Bowel Syndrome
Brint, E. K., MacSharry, J., Fanning, A., Shanahan, F., & Quigley, E. M. M. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.438 · Cited by 205
Chen, J., Zhang, W., Lin, J., Wang, F., Wu, M., Chen, C., Zheng, Y., Peng, X., Li, J., & Yuan, Z. (2014) · Molecular Therapy · doi:10.1038/mt.2013.212 · Cited by 159
Rodriguez, R., Jung, C.-L., Gabayan, V., Deng, J. C., Ganz, T., Nemeth, E., & Bulut, Y. (2014) · Infection and Immunity · doi:10.1128/iai.00983-13 · Cited by 127
Wang, H., Wu, B., Li, L., Hu, L., Lin, J., Jiang, C., Cai, G., & Shen, Q. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2016.10.002 · Cited by 32
Yong, L., Li, M., Gao, Y., Deng, Y., Liu, W., Huang, D., Ren, C., Liu, M., Shen, J., & Hou, X. (2017) · Scientific Reports · doi:10.1038/srep46765 · Cited by 12
Du, Y., Yan, H., Zou, S., Khera, T., Li, J., Han, M., Yang, X., Wang, B., Liu, J., Sun, S., et al. (2021) · Hepatology Communications · doi:10.1002/hep4.1676 · Cited by 9
Self-citation
Metadata
- Authors
- Wu, J., Meng, Z., Jiang, M., Pei, R., Trippler, M., Broering, R., Bucchi, A., Sowa, J.-P., Dittmer, U., Yang, D., Roggendorf, M., Gerken, G., Lu, M., & Schlaak, J. F.
- Venue
- Hepatology
- Published
- 2009-04
- Volume
- 49
- Issue
- 4
- Pages
- 1132-1140
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2145333397
- Cited by
- 318
- References
- 32
- FWCI
- 10.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.